# Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®

Study · id `cardio:ct-nct04570865` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04570865](<https://clinicaltrials.gov/study/NCT04570865>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04570865

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04570865. Allocation not applicable; no masking; primary purpose treatment. Start 2020-12-01 (anticipated); primary completion 2021-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04570865, source copy `cardio:ctgov-nct04570865-2020-09-30`, retrieved 2026-10-26)
- Planned start: 2020-12-01 (anticipated) (ClinicalTrials.gov record NCT04570865, source copy `cardio:ctgov-nct04570865-2020-09-30`, retrieved 2026-10-26)
- Primary completion: 2021-12-01 (anticipated) (ClinicalTrials.gov record NCT04570865, source copy `cardio:ctgov-nct04570865-2020-09-30`, retrieved 2026-10-26)
- Completion: 2022-02-01 (anticipated) (ClinicalTrials.gov record NCT04570865, source copy `cardio:ctgov-nct04570865-2020-09-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04570865, source copy `cardio:ctgov-nct04570865-2020-09-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04570865-2020-09-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin And Pulmonary Artery Hemodynamics in Heart Failure With Reduced Ejection Fraction Patients With CardioMEMS®
- Acronym: DAPA-MEMS
- Condition: Heart Failure, Systolic
- Intervention (Drug): Dapagliflozin
- Intervention (Device): CardioMEMS
- Lead sponsor: Scripps Health
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Scripps Health (`cardio:org-scripps-health`)

## Provenance

Content hash: f6781c6e0dc58f1c61775ff2b0fdc506fa696e2338d55f78dc4595f7df7cac01
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
